Background
==========

Antibodies to a cytosolic soluble liver antigen (SLA), detected originally by an inhibition ELISA using cytosolic liver fractions in a sub-group of patients with autoimmune hepatitis (AIH) negative for other autoantibodies, have recently been also reported in adult patients with anti-nuclear and/or smooth muscle antibody (ANA/SMA) positive type 1 AIH and in seronegative patients with a form of cryptogenic hepatitis resembling type 1 AIH \[[@B1]-[@B6]\]. In pediatric patients, anti-SLA has been described not only in type 1 AIH but also in anti-liver kidney microsomal-1 antibody positive type 2 AIH and autoimmune sclerosing cholangitis \[[@B7]-[@B10]\]. Anti-SLA is specific for these autoimmune liver diseases, where it is associated with a more severe course and is virtually absent in non-hepatic autoimmune disorders \[[@B1]-[@B9]\]. The target of anti-SLA has been identified by several groups as a \~50 kDa UGA serine tRNA-associated protein complex (tRNP^(Ser)Sec^), through the screening of cDNA libraries \[[@B2]-[@B4],[@B7]\]. Anti-tRNP^(Ser)Sec^antibodies have been detected in up to 90% of serum samples positive for SLA by the original inhibition ELISA \[[@B1]-[@B8]\].

Using anti-SLA positive sera against rat liver cytosolic fraction in one and two-dimensional immunoblotting analyses and through peptide mass fingerprint analysis, following MALDI-TOF mass spectrometry, Ballot et al. \[[@B11]\] identified four isoforms of α-enolase, -- a cytosolic antigen of 48--50 kDa --, as the major target of anti-SLA positive sera. These findings challenge the notion that tRNP^(Ser)Sec^is the sole target of anti-SLA antibodies \[[@B2]-[@B8]\]. Critically, no absorption studies were performed with purified α-enolase to confirm this proposal \[[@B11]\]. Moreover, α-enolase has been described as an antigen in several autoimmune disorders totally unrelated to autoimmune hepatitis \[[@B12]-[@B18]\].

Using recombinant tRNP^(Ser)Sec^antigen as competitor in inhibition experiments it has been found removal of the 50 kDa band immunofixed by SLA positive sera from immunoblots of primate liver homogenate \[[@B19]\]. Though this finding indicates tRNP^(Ser)Sec^as a major component of SLA, a view apparently shared by Ballot et al, several questions still remain unanswered:

1\. Are there any differences in α-enolase expression between rat -- used by Ballot et al \[[@B11]\] -- and primate liver homogenate -- used by our study \[[@B19]\] -- that could explain the discrepancy between these studies?

2\. Is it true that failure of proteomic analysis to detect tRNP^(Ser)Sec^is due to its presence in trace amounts in the supernatant of liver homogenate \[[@B11]\]?

3\. What is the reactivity of SLA positive and negative sera against recombinant α-enolase?

4\. How do we explain the apparent paradox of SLA being identified as α-enolase by proteomic analysis and as tRNP^(Ser)Sec^by the screening of cDNA libraries? Do α-enolase and tRNP^(Ser)Sec^cross-react?

In the present study, we have investigated reactivity of SLA positive sera against α-enolase and tRNP^(Ser)Sec^using rat and primate liver homogenate and the recombinant antigens.

Methods
=======

Patients
--------

Thirty-three serum samples, 11 from SLA-positive patients and 22 from SLA negative controls were investigated. SLA-positive patients included 8 paediatric patients with AIH1 \[7 female, median age 12, range 5--17 years, all ANA positive, median immunofluorescence (IFL) titre: 1/320, range 1/80--1/1280\] and 3 adults with AIH/PBC overlap syndrome, (2 female, median age 56, range 47--65), all but one AMA positive (1/5120), and ANA positive (median tire 1/320, range 1/80--1/640). Eleven case-matched SLA negative patients were tested as pathological controls including 8 with AIH1 and 3 with AIH/PBC overlap syndrome. Eleven demographically matched healthy subjects including 8 children (7 female, median age 11, range 6--16) and 3 adults (2 female, median age 53, range 42--63) negative for SLA were also tested as controls.

Antibody Detection
------------------

All sera have been tested for conventional antibodies by indirect IFL using rodent liver, kidney, stomach tissues.

SLA antibodies were detected by a modified inhibition ELISA \[[@B1]\] and confirmed by immunoblot using human liver homogenate \[[@B20]\]. Autoantibody reactivity was further evaluated using preparations of primate (Euroimmun, Lubeck, Germany) and rat (AID Autoimmun Diagnostika GmbH, Strassberg, Germany) liver homogenates, according to manufacturers\' instructions. Anti-α-enolase antibody reactivity has been tested by immunoblot using recombinant α-enolase, as described previously \[[@B17]\]. Briefly, the complete complementary DNA (cDNA) encoding human α-enolase was isolated from a cDNA expression library derived from synoviocytes obtained from a patient with rheumatoid arthritis (Stratagene, La Jolla, CA) and immunoscreened with goat anti-enolase antibodies. This cDNA was subcloned in frame in the pSPUTK in vitro translation vector (Stratagene) using the Apa I and Bam HI restriction sites. The translation product was synthesized as a separated biotinylated polypeptide, purified by SoftLink Soft Release Avidin Resin (Promega, Madison, WI), migrated in SDS-PAGE, according to the method of Laemmli, and electrotransferred onto a nitrocellulose membrane \[[@B17]\]. The filters were then incubated with goat anti-enolase antibodies (see below), a monospecific anti-α-enolase antibody positive serum from a patient with rheumatoid arthritis or with individual serum samples, in Tris buffered saline, 0.05% Tween 20, 5% dry milk for 2 hours. After washing, the filters were incubated for 1 hour with 1:15,000-diluted peroxidase-conjugated goat anti-human IgG (Sigma-Aldrich) in 0.05% TBST-milk. The filters were washed and revealed by a chemiluminescence reaction (Supersignal; Pierce, Rockford, IL) \[[@B17]\].

An affinity purified goat polyclonal anti-α-enolase IgG antibody raised against a peptide mapping near the carboxyl-terminus of human α-enolase, which is common to α, β, and γ isoforms of mouse, rat and human enolase (200 μg/ml; Santa Cruz Biotechnology, Santa Cruz, California, USA) was used as reference serum sample at a dilution of 1:100, according to the manufacturer\'s instructions.

Anti-tRNP^(Ser)Sec^antibody reactivity was detected by ELISA or dot blot using recombinant tRNP^(Ser)Sec^antigen (Euroimmun). A high-titre anti-tRNP^(Ser)Sec^antibody positive serum was used as a positive control.

Inhibition Studies
------------------

To investigate whether the 50 kDa band immunofixed by anti-SLA is tRNP^(Ser)Sec^, inhibition experiments were performed using 3 anti-SLA positive serum samples, diluted at 1/1000, and pre-incubated with solid phase recombinant tRNP^(Ser)Sec^(Euroimmun, UK), as previously described \[[@B19]\].

Results and Discussion
======================

The affinity purified IgG antibody directed to human α-enolase gave a band of approximately 48 kDa in both human and rat liver homogenates as shown in Figure [1](#F1){ref-type="fig"}. A high titre anti-tRNP^(Ser)Sec^antibody serum gave a single band of \~50 kDa in both liver preparations (Figure [1](#F1){ref-type="fig"}). All but one anti-SLA antibody positive sera reacted with a \~50 kDa band similar to that obtained by the high titre anti-tRNP^(Ser)Sec^antibody serum in rat liver preparations (Figure [2](#F2){ref-type="fig"}) but none immunofixed a 48 kDa band. All anti-SLA antibody positive sera reacted strongly with the recombinant full length tRNP^(Ser)Sec^protein both in ELISA (mean titre 87 ± 23 RU/ml, cut off: 20 RU/ml) and dot blot. None of the anti-SLA negative sera reacted with tRNP^(Ser)Sec^. Anti-SLA positive, and anti-SLA negative sera reacted equally against recombinant α-enolase by immunoblot with 5/9 cases in each group giving a strong band (Figure [3](#F3){ref-type="fig"}).

![Immunoblot patterns produced by anti-α-enolases and anti-tRNP^(Ser)Sec^antibodies on electrophoretically separated primate and rat liver homogenates and dot blot results with recombinant tRNP^(Ser)Sec^. In both rat and primate liver preparations, a band of \~48 kDa is immunofixed by a polyclonal goat IgG anti-α-enolase specific antibody; a band of \~50 kDa is immunofixed by a serum containing a high-titre anti-tRNP^(Ser)Sec^antibody. Anti-α-enolase antibody does not recognize tRNP^(Ser)Sec^by dot blot analysis.](1740-2557-1-4-1){#F1}

![Immunoblot patterns produced on rat liver homogenate by (lane 1) a polyclonal goat IgG anti-α-enolase specific antibody; (lanes 2--5) four representative anti-soluble liver antigen (SLA) positive sera; (lane 6) a reference serum containing high-titre anti-tRNP^(Ser)Sec^antibody.](1740-2557-1-4-2){#F2}

![Immunoblot patterns obtained using 9 SLA positive and 9 SLA negative serum samples against recombinant α-enolase. A polyclonal goat IgG anti-α-enolase specific antibody has been used as a reference positive serum. Ab, antibody; ag, antigen](1740-2557-1-4-3){#F3}

Pre-incubation of anti-SLA positive sera with tRNP^(Ser)Sec^completely abolished the 50 kDa band immunofixed in either rat or human liver preparation. In contrast, a parallel experiment where the anti-α-enolase antiserum was pre-incubated with recombinant tRNP^(Ser)Sec^left unaltered the reactivity to the 48 kDa band.

The findings of the present study indicate that α-enolase and tRNP^(Ser)Sec^are both expressed in primate and rat liver and have a respective MW of 48 and 50 kDa. They also show that anti-tRNP^(Ser)Sec^-- but not anti-α-enolase -- correlates with anti-SLA antibody reactivity suggesting that the target of anti-SLA antibody is tRNP^(Ser)Sec^and not α-enolase \[[@B1]-[@B9],[@B19]\].

However, Ballot et al \[[@B11]\] state that α-enolase is a major SLA antigen since rat α-enolases have MW of 47.4 to 47.5 and Pi values of 5.8 to 6.2. These characteristics do not match the MW (48.8) and Pi (8.6) of tRNP^(Ser)Sec^. Ballot et al \[[@B11]\], however, show a Coomassie stained 2D-gel over the Pi range 6 to 11 and an immunoblot of this gel with several bands of a Pi above 8, but have not investigated these bands by MALDI-TOF analysis being therefore unable to rule out their possible relation to tRNP^(Ser)Sec^.

Conclusion
==========

All the above observations indicate that tRNP^(Ser)Sec^is the most likely target of anti-SLA.
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